Tuberculosis Infection and Comorbidities: A Public Health Issue in Baja California, Mexico

According to the World Health Organization (WHO), tuberculosis (TB) remains a significant global health challenge, with approximately 10 million new cases and 1.4 million deaths reported in 2020. TB disproportionately affects low- and middle-income countries, where factors such as migrant population, malnutrition, type 2 diabetes, human immunodeficiency virus (HIV) co-infection, and COVID-19 exacerbate its impact. TB also leads to substantial economic losses due to decreased productivity and high healthcare costs. Despite advances in treatments, TB remains a major public health issue, particularly in poorer regions. In Mexico, TB is considered a moderate-incidence disease, with higher prevalence in border states, mainly due to population displacements. Effective TB control requires collaboration between Mexico and the United States of America given the high cross-border human movement, like in the Baja California State that reported predominantly pulmonary TB cases. Effective management of TB involves rapid diagnosis and identification of antibiotic resistance. Techniques such as PCR, high-resolution computed tomography (HRCT), and/or Xpert MTB/RIF have enhanced diagnostic accuracy. Future perspectives about TB management focus on developing new drugs and vaccines to combat drug-resistant strains, and the comorbidities associated, which must be addressed to reinforce of health public programs.